April 20, 2026 · Form 4 insider transaction
Bain Capital Life Sciences Investors, LLC bought 1,562,500 shares of Kailera Therapeutics, Inc. at $16.00 per share, a transaction worth $25.00M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 0 days after the transaction.
Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments").; Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.